StreetInsider.com News Articles

Morgan Stanley tracks prescription trends for US neurology drugs

Fri, 05 Jun 2026 08:59:03 -0400

Investing.com -- Morgan Stanley released its weekly prescription tracking data for select US neurology products based on IQVIA data for the week ending May 29.

The US antipsychotic market showed total prescriptions grew 2.9% year-over-year for the week, which included the Memorial Day holiday. The rolling 4-week total prescription count increased 2.6% year-over-year, while the rolling 12-week count rose 2.2% year-over-year.

Week-over-week, total prescriptions for antipsychotics declined 8.8%, compared to a 2.5% increase in the prior week.

Total prescriptions for bipolar depression medications fell 8.1% week-over-week. The rolling 4-week total prescription count decreased 1.7% week-over-week. Year-over-year growth stood at 3.8% for the current

Morgan Stanley tracks prescription trends for US neurology drugs

Fri, 05 Jun 2026 08:59:03 -0400

Investing.com -- Morgan Stanley released its weekly prescription tracking data for select US neurology products based on IQVIA data for the week ending May 29.

Week-over-week, total prescriptions for antipsychotics declined 8.8%, compared to a 2.5% increase in the prior week.

Morgan Stanley tracks prescription trends for US neurology drugs

Fri, 05 Jun 2026 08:59:03 -0400

Investing.com -- Morgan Stanley released its weekly prescription tracking data for select US neurology products based on IQVIA data for the week ending May 29.

Week-over-week, total prescriptions for antipsychotics declined 8.8%, compared to a 2.5% increase in the prior week.

Morgan Stanley tracks prescription trends for US neurology drugs

Fri, 05 Jun 2026 08:59:03 -0400

Investing.com -- Morgan Stanley released its weekly prescription tracking data for select US neurology products based on IQVIA data for the week ending May 29.

Week-over-week, total prescriptions for antipsychotics declined 8.8%, compared to a 2.5% increase in the prior week.

Axsome Therapeutics Presents New SYMBRAVO® Data at the Americal Headache Society (AHS) 68th Annual Scientific Meeting

Thu, 04 Jun 2026 07:00:00 -0400

NEW YORK, June 04, 2026 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced presentations of new SYMBRAVO^® data at the Americal Headache Society (AHS) 68th Annual Scientific Meeting being held from June 4-7 in Orlando, FL.

Details of the presentations are as follows:

Title: SYMBRAVO (MoSEIC™ meloxicam and rizatriptan) for the Acute Treatment of Migraine: Post-hoc Composite Efficacy and Return to Function Endpoint Analysis from MOMENTUM
Presentation Date and Time: Thursday, June 4, 6:00 -

Axsome Therapeutics Presents New SYMBRAVO® Data at the Americal Headache Society (AHS) 68th Annual Scientific Meeting

Thu, 04 Jun 2026 07:00:00 -0400

Details of the presentations are as follows:

Title: SYMBRAVO (MoSEIC™ meloxicam and rizatriptan) for the Acute Treatment of Migraine: Post-hoc Composite Efficacy and Return to Function Endpoint Analysis from MOMENTUM
Presentation Date and Time: Thursday, June 4, 6:00 -

H.C. Wainwright Reiterates Buy Rating on Axsome Therapeutics (AXSM)

Thu, 04 Jun 2026 06:40:58 -0400

H.C. Wainwright analyst Raghuram Selvaraju reiterated a Buy rating and $290.00 price target on Axsome Therapeutics (NASDAQ: AXSM).

The analyst commented: "Yesterday, Axsome announced that it had resolved all patent litigation related to Axsome’s product SUNOSI (solriamfetol). The litigation proceedings resulted from submission of Abbreviated New Drug Applications (ANDAs) to the FDA by companies seeking approval to market generic versions of SUNOSI in the United States. Axsome resolved all outstanding SUNOSI patent litigation upon entering into a settlement agreement with the only remaining first-to-file generic applicant with pending patent litigation related to Axsome’s product SUNOSI. As part of the resolution of

Form 8-K Axsome Therapeutics, For: Jun 03

Wed, 03 Jun 2026 09:04:00 -0400

si-local-file:///var/storage/secattach/20260603/26596520.html

Form 8-K Axsome Therapeutics, For: Jun 03

Wed, 03 Jun 2026 09:04:00 -0400

si-local-file:///var/storage/secattach/20260603/26596520.html

Axsome settles SUNOSI patent litigation, allows generics starting 2040

Wed, 03 Jun 2026 07:04:08 -0400

Axsome Therapeutics Inc. (NASDAQ: AXSM) announced it has resolved all patent litigation related to its SUNOSI (solriamfetol) drug product, according to a company statement. The litigation arose from companies submitting applications to the Food and Drug Administration seeking approval to market generic versions of SUNOSI in the United States.

Under the settlement agreement, Axsome will grant five companies rights to sell generic versions of SUNOSI beginning September 1, 2040, if pediatric exclusivity is granted for the drug, or March 1, 2040, if no pediatric exclusivity is granted. The generic sales are subject to FDA approval and standard agreement conditions.

The company settled

Axsome settles SUNOSI patent litigation, allows generics starting 2040

Wed, 03 Jun 2026 07:04:08 -0400

The company settled

Axsome Therapeutics Announces Settlement Resolving All SUNOSI® (solriamfetol) Patent Litigation

Wed, 03 Jun 2026 07:00:00 -0400

NEW YORK, June 03, 2026 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM) (Axsome), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced that it has resolved all patent litigation related to Axsome’s product SUNOSI (solriamfetol). The litigations resulted from submission of Abbreviated New Drug Applications to the U.S. Food and Drug Administration by companies seeking approval to market a generic version of SUNOSI in the United States.

Axsome resolved all outstanding SUNOSI patent litigation upon entering into a settlement agreement with the only remaining first-to-file

Axsome Therapeutics Announces Settlement Resolving All SUNOSI® (solriamfetol) Patent Litigation

Wed, 03 Jun 2026 07:00:00 -0400

Axsome resolved all outstanding SUNOSI patent litigation upon entering into a settlement agreement with the only remaining first-to-file

Form 4 Axsome Therapeutics, For: May 29 Filed by: Coleman Mark

Tue, 02 Jun 2026 19:00:00 -0400

si-local-file:///var/storage/secattach/20260602/26593801.html

Form 4 Axsome Therapeutics, For: May 29 Filed by: Coleman Mark

Tue, 02 Jun 2026 19:00:00 -0400

si-local-file:///var/storage/secattach/20260602/26593801.html

Form 144 Axsome Therapeutics, Filed by: Coleman Mark

Tue, 02 Jun 2026 16:10:00 -0400

si-local-file:///var/storage/secattach/20260602/26591711.html

Form 144 Axsome Therapeutics, Filed by: Coleman Mark

Tue, 02 Jun 2026 16:10:00 -0400

si-local-file:///var/storage/secattach/20260602/26591711.html

Form 144 Axsome Therapeutics, Filed by: Coleman Mark

Mon, 01 Jun 2026 16:06:00 -0400

si-local-file:///var/storage/secattach/20260601/26583485.html

Form 144 Axsome Therapeutics, Filed by: Coleman Mark

Mon, 01 Jun 2026 16:06:00 -0400

si-local-file:///var/storage/secattach/20260601/26583485.html

Axsome partners with Headache Alliance for migraine awareness month

Mon, 01 Jun 2026 07:03:37 -0400

Axsome Therapeutics Inc. (NASDAQ: AXSM) announced its partnership with the Headache Alliance to support educational initiatives during Migraine and Headache Awareness Month in June.

The biopharmaceutical company is backing the first annual Headache in the City educational campaign scheduled for June 15 in New York City. Axsome's headquarters at One World Trade Center will be illuminated in purple on June 4 through the building's Spireworks program to promote migraine awareness.

"People living with migraine and headache disorders deserve to be seen, believed, and supported with information and care that reflect the seriousness of these diseases," said Julienne Verdi, Executive Director of The

Axsome Therapeutics Partners with the Headache Alliance to Highlight the Impact of Migraine During Migraine and Headache Awareness Month

Mon, 01 Jun 2026 07:00:00 -0400

NEW YORK, June 01, 2026 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today highlighted its commitment to the migraine community by supporting educational initiatives during Migraine and Headache Awareness Month this June.

“People living with migraine and headache disorders deserve to be seen, believed, and supported with information and care that reflect the seriousness of these diseases,” said Julienne Verdi, Executive Director of The Headache Alliance and the Alliance for Headache Disorders Advocacy. “Awareness campaigns like Headache in

Axsome Therapeutics Partners with the Headache Alliance to Highlight the Impact of Migraine During Migraine and Headache Awareness Month

Mon, 01 Jun 2026 07:00:00 -0400

Form 144 Axsome Therapeutics, Filed by: Coleman Mark

Fri, 29 May 2026 16:09:00 -0400

si-local-file:///var/storage/secattach/20260529/26575167.html

Form 144 Axsome Therapeutics, Filed by: Coleman Mark

Fri, 29 May 2026 16:09:00 -0400

si-local-file:///var/storage/secattach/20260529/26575167.html

Axsome Therapeutics to Participate in Upcoming Investor Conferences

Wed, 27 May 2026 07:00:00 -0400

NEW YORK, May 27, 2026 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced that it will participate in the following upcoming investor conferences in June:

William Blair 46th Annual Growth Stock Conference
Fireside Chat: Wednesday, June 3, 2026, at 2:40 p.m. CT in Chicago, IL

Jefferies Global Healthcare Conference
Fireside Chat: Thursday, June 4, 2026, at 10:30 a.m. ET in New York, NY

Goldman Sachs 47th Annual Global Healthcare Conference
Fireside Chat: Monday,